Vol 118, No 1 (Supplement) 2013
Original Article

Modifications in relaxin’s serum levels during acetatefree biofiltration (AFB): only a new biomarker?

PDF
  • Valeria Cernaro,
  • Antonio Lacquaniti,
  • Grazia Giorgianni,
  • Davide Bolignano,
  • Michele Buemi

Published 2014-01-11

Keywords

  • acetate-free haemodialysis,
  • blood pressure,
  • pleiotropic hormone,
  • relaxin

How to Cite

Cernaro, V., Lacquaniti, A., Giorgianni, G., Bolignano, D., & Buemi, M. (2014). Modifications in relaxin’s serum levels during acetatefree biofiltration (AFB): only a new biomarker?. Italian Journal of Anatomy and Embryology, 118(1), 98–99. Retrieved from https://oajournals.fupress.net/index.php/ijae/article/view/3299
Copyright Notice

Abstract

Aims.We evaluated relaxin’s behaviour during a haemodialytic session and the effects of its intradialytic variability on blood pressure. Methods. We enrolled 25 patients and evaluated relaxin’s levels during a haemodialytic session. We also dosed interdialytic relaxin and enrolled 10 healthy subjects and 16 patients with III stage chronic renal failure as controls. Results. Haemodialyzed patients have relaxin’s baseline concentrations higher than healthy controls, but lower than chronic patients. During the treatment, relaxin is removed; it increases again throughout the interdialytic phase. Furthermore, relaxin’s pre- haemodialytic concentration positively and significantly correlates with systolic, diastolic, and mean BP; such correlations disappear at the end of the treatment. Conclusion. Relaxin’s removal during the treatment may intervene in the pathogenesis of intradialytic hypertension. Hence, relaxin could be not only a new biomarker but also an active player in the intradialytic variations of blood pressure.

PDF